<DOC>
	<DOCNO>NCT00001012</DOCNO>
	<brief_summary>To study tolerance safety increase dos AL-721 patient persistent generalize lymphadenopathy ( PGL ) symptomatic HIV infection , obtain preliminary information effectiveness AL-721 human immunodeficiency virus ( HIV ) HIV-infected person PGL symptomatic HIV infection . Although zidovudine ( AZT ) prolong life certain AIDS patient , cure AIDS also toxic effect many patient . Therefore , necessary test drug HIV-infected patient . AL-721 mixture lipid ( fat ) extract egg yolk . Laboratory test suggest might inhibit infectivity HIV . AL-721 try far patient short period time find well tolerate .</brief_summary>
	<brief_title>A Study AL721 HIV-Infected Patients With Swollen Lymph Nodes</brief_title>
	<detailed_description>Although zidovudine ( AZT ) prolong life certain AIDS patient , cure AIDS also toxic effect many patient . Therefore , necessary test drug HIV-infected patient . AL-721 mixture lipid ( fat ) extract egg yolk . Laboratory test suggest might inhibit infectivity HIV . AL-721 try far patient short period time find well tolerate . Patients receive AL-721 twice daily . The first dose take empty stomach 1 hour fat-free breakfast , specific instruction give food allow ; second dose take least 3 hour even meal . No snack permit even meal even dose study medication . The study schedule last 16 week treatment 4 week follow-up . Throughout study , frequent blood sample take arm vein . The blood sample study evaluate change patient 's immune system , toxic effect might detect blood , change presence HIV blood .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<criteria>Inclusion Criteria Persistent generalize lymphadenopathy ( PGL ) ( CDCGroup III ) , define palpable lymphadenopathy ( node 1 cm great ) two noncontiguous extrainguinal site persist &gt; 3 month absence illness HIV infection account finding . AIDS relate complex ( ARC ) , define presence least one follow finding within 12 month prior entry absence concurrent illness condition HIV infection explain finding : Any finding define CDCGroup IV A . History one find define CDCGroup IV C2 . Patients ARC symptom also PGL enrol protocol ARC patient . A positive antibody HIV federally license ELISA test kit within 30 day entry . Concurrent Medication : Allowed : Topical oral antifungal , antiviral , antibiotic agent treat oral candidiasis , herpes simplex , herpes zoster , bacterial infection develop course study . Exclusion Criteria Exclude hemophiliac . Active substance abuse . Alcohol consumption keep minimum . Coexisting Condition : Patients follow exclude : Hemophilia . History presence AIDSdefining opportunistic infection malignancy . AIDS relate complex ( ARC ) patient prior ( within last 12 month ) current history diarrhea define = &gt; 3 liquid stool per day persisting longer 1 month . Significant malabsorption : Greater 10 percent weight loss within past 3 month serum carotene &lt; 75 IU/ml vitamin A &lt; 75 IU/ml . Significant cardiac , liver , renal , neurologic disorder . Active ARCdefining secondary infection ( oral candidiasis , oral hairy leukoplakia , multidermatomal herpes zoster , recurrent nontyphoidal Salmonella bacteremia Nocardiosis ) undergo therapy prophylaxis within 7 day study entry . Active tuberculosis treatment . Concurrent neoplasm basal cell carcinoma skin situ carcinoma cervix . Concurrent Medication : Excluded : Any medication interfere assessment AL721 , include nutritional supplement , vitamin , laxative , overthecounter product contain lecithin . Chemoprophylaxis Pneumocystis carinii ( PCP ) , candida , herpes simplex , herpes zoster infection , bacterial infection . Intravenous topical oral antifungal , antiviral , antibiotic agent treat oral candidiasis , herpes simplex , herpes zoster , bacterial infection develop course study . Systemic chemotherapy . Prior Medication : Excluded within 30 day study entry : Any investigational drug . Biologic response modifier . Corticosteroids . Chemotherapeutic agent . Excluded within 90 day study entry : Any antiretroviral agent AL721 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2002</verification_date>
	<keyword>Virus Replication</keyword>
	<keyword>T-Lymphocytes</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AL 721</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>